An article by our collaborator Irene Tarragó

As I write these lines, we are approaching February 13rd, the day on which this year we celebrate International Epilepsy Day, as you know that it is celebrated on the second Monday of February.

However, people with epilepsy and their families live with the disease 365 days a year. It is necessary to have these special days in which the media, the administrations, the associations echo this disease, talk about it, put the focus on people who live with it and make society aware of what it is and what it represents. It is true that the Associations do not stop doing so throughout the year, but we do not deserve the attention of the media and that means that society still does not know the ins and outs of epilepsy.

People with epilepsy and their families live with the disease 365 days a year

Knowledge makes fear disappear. If you know what you are facing and what you must do, the way to accept it has already begun. And the same goes for people who do not have the disease: if they know what the disease is, what they can do in case of a seizure, that it can happen to them at any time… if they have even a minimal knowledge about epilepsy, bullying in schools or lack of work will decrease. You cannot discriminate on the basis of a disease.

With the few means I have, I try to reveal as much as I can the characteristics of this disease. As for this coming day, I am trying to close a radio interview and an informative round table. They are small things, but I could not do nothing knowing that with these things I can help, even if it is only one person.

A hug to all of you who have epilepsy and to your family members.

And always calm, very calm.

Worldwide, some 50 million people suffer from epilepsy
About 80% of patients live in low- and middle-income countries
An estimated 70% of people with epilepsy could live seizure-free if properly diagnosed and treated
In many parts of the world, people with epilepsy and their families suffer from stigma and discrimination

Leave a Reply

Open chat
1
Contact with us now
Chat with Anna
¡Hola! 👋🏻
Soy Anna, ¿en qué puedo ayudarte?

The user who fills in the information requested in this form declares to be entitled to do so and is solely responsible for the accuracy and completeness of the data and information entered, expressly exonerating MJN NEUROSERVEIS of any liability that may arise for this entity on the occasion of the information provided through this form.

Yes, I accept

L’usuari que complimenta la informació requerida al present formulari declara estar legitimat per això i es fa responsable exclusiu de la veracitat i integritat de les dades i informació que introdueix, exonerant expressament a MJN NEUROSERVEIS de qualsevol responsabilitat que es pugi generar per aquesta entitat amb ocasió de la informació facilitat a través del present formulari.

Si, accepto

El usuario que cumplimenta la información requerida en el presente formulario declara estar legitimado para ello y se hace responsable exclusivo de la veracidad e integridad de los datos e información que introduce, exonerando expresamente a MJN NEUROSERVEIS de cualquier responsabilidad que pudiera generarse para esta entidad con ocasión de la información facilitada a través del presente formulario.

Sí, acepto

Save the date

The next Saturday 21st of November at 4 pm, you will be able to know first hand our product: mjn-SERAS.
mjn-SERAS is a healthcare product that sends a warning signal when the risk of epileptic seizures is high, to the affected person and their trusted contacts.

Sign up now!


    mjn-SERAS is a medical device with CE marking according to the European Directive 93/42/EEC and the Royal Decree RD. 1591/2009.
    Contraindications: Do not use the product if you suffer from an infection in the ear canal or if you suffer from a skin lesion in the vicinity of the product's area of influence.
    Considerations: This medical product works with an APP only on Android phones. The results tested are 96% sensitivity and 94% specificity.
    CPSP20103CAT.

    Save the date

    El próximo sábado 21 de noviembre a las 4 de la tarde, podrás conocer de primera mano nuestro producto: mjn-SERAS.
    mjn-SERAS es un producto sanitario que lanza una señal de aviso cuando el riesgo de crisis de epilepsia es elevado, a la persona afectada y a sus contactos de confianza.

    ¡Inscríbete!

      mjn-SERAS es un producto sanitario con marcado CE conforme a la Directiva Europea 93/42/EEC y el Real Decreto RD. 1591/2009.
      Contraindicaciones: No usar el producto en caso de padecer una infección en el canal auditivo o en caso de padecer una lesión cutánea en las proximidades del área de influencia del producto.
      Consideraciones: Este producto sanitario funciona con una APP solo en teléfonos Android. Los resultados testeados son 96% de sensibilidad y 94% de especificidad.
      CPSP20103CAT.